ST8SIA6

Summary

ST8SIA6 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6, HGNC:23317) is a protein-coding gene on chromosome 10p12.33, encoding Alpha-2,8-sialyltransferase 8F (P61647). Alpha-2,8-sialyltransferase that prefers O-glycans to N-glycans or glycolipids as acceptor substrates.

This gene encodes a member of the glycosyltransferase 29 protein family. Members of this protein family synthesize sialylglycoconjugates. Sialylation may contribute to multidrug resistance in cancer cells. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 338596 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 57 total
• MANE Select transcript: NM_001004470

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23317
Approved symbol	ST8SIA6
Name	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6
Location	10p12.33
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000148488
Ensembl biotype	protein_coding
OMIM	610139
Entrez	338596

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 nonsense_mediated_decay

ENST00000377602, ENST00000440449, ENST00000648997

RefSeq mRNA: 2 — MANE Select: NM_001004470 NM_001004470, NM_001345961

CCDS: CCDS31158

Canonical transcript exons

ENST00000377602 — 8 exons

Exon	Start	End
ENSE00000985558	17327014	17327126
ENSE00000985559	17323065	17323157
ENSE00001474502	17315421	17321346
ENSE00001679406	17453559	17453657
ENSE00001720469	17331408	17331552
ENSE00001763915	17390531	17390620
ENSE00001829821	17454155	17454595
ENSE00003243191	17359514	17359600

Expression profiles

Bgee: expression breadth ubiquitous, 130 present calls, max score 76.28.

FANTOM5 (CAGE): breadth broad, TPM avg 2.9875 / max 343.7639, expressed in 583 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
108537	1.9457	481
108535	0.3179	145
108536	0.2445	114
108534	0.2061	97
108538	0.1574	87
108540	0.0708	41
108539	0.0451	14

Top tissues by expression

135 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.28	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	73.40	gold quality
substantia nigra	UBERON:0002038	73.21	gold quality
cerebellar vermis	UBERON:0004720	72.92	gold quality
apex of heart	UBERON:0002098	71.25	gold quality
heart left ventricle	UBERON:0002084	69.68	gold quality
right atrium auricular region	UBERON:0006631	68.93	gold quality
heart	UBERON:0000948	68.35	gold quality
colonic epithelium	UBERON:0000397	67.74	silver quality
lung	UBERON:0002048	67.58	gold quality
thymus	UBERON:0002370	66.86	silver quality
leukocyte	CL:0000738	66.73	gold quality
cortical plate	UBERON:0005343	66.44	gold quality
monocyte	CL:0000576	66.39	gold quality
hypothalamus	UBERON:0001898	65.28	gold quality
quadriceps femoris	UBERON:0001377	64.88	gold quality
granulocyte	CL:0000094	64.57	gold quality
prefrontal cortex	UBERON:0000451	63.81	gold quality
upper lobe of left lung	UBERON:0008952	63.32	gold quality
spinal cord	UBERON:0002240	63.26	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	63.24	gold quality
superior frontal gyrus	UBERON:0002661	62.88	gold quality
Ammon’s horn	UBERON:0001954	62.47	gold quality
right lung	UBERON:0002167	62.30	gold quality
ganglionic eminence	UBERON:0004023	61.79	gold quality
right coronary artery	UBERON:0001625	61.48	gold quality
primary visual cortex	UBERON:0002436	61.41	gold quality
caudate nucleus	UBERON:0001873	60.95	gold quality
frontal cortex	UBERON:0001870	60.81	gold quality
placenta	UBERON:0001987	60.77	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	20.85
E-HCAD-25	yes	9.78
E-CURD-112	yes	7.63
E-ANND-3	yes	6.46
E-ENAD-17	no	133.46

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GATA3

miRNA regulators (miRDB)

29 targeting ST8SIA6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-217-5P	99.49	69.93	1419
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-6807-3P	99.15	69.23	1275
HSA-MIR-491-5P	99.13	65.98	1468
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-6770-5P	98.97	66.76	1853
HSA-MIR-4317	98.49	67.09	987
HSA-MIR-1912-5P	97.94	67.98	832
HSA-MIR-1270	96.94	66.65	931
HSA-MIR-620	96.94	66.79	888

Literature-anchored findings (GeneRIF, showing 8)

• NK cells consistently expressed mRNA encoding ST8Sia VI, which creates alpha2,8-linked disialic acids on O-linked glycans of glycoproteins and NK cells variably expressed high levels of ST8Sia V mRNA required for GT3 expression. (PMID:16857734)
• ST8SIA6 gene is involved in the development of multidrug resistance via PI3K/Akt pathway in chronic myeloid leukemia. (PMID:25855199)
• Genome-wide association study reveals two novel risk alleles for incident obstructive sleep apnea in the EPISONO cohort. (PMID:31786426)
• Profiling of specific long non-coding RNA signatures identifies ST8SIA6-AS1 AS a novel target for breast cancer. (PMID:33037712)
• The Diagnostic Value of Serum ST8SIA6-AS1 as Biomarker in Hepatocellular Carcinoma. (PMID:33337846)
• ST8SIA6-AS1 promotes the development of hepatocellular carcinoma cells through miR-338-3p/NONO Axis. (PMID:33722502)
• The alpha2,8-sialyltransferase 6 (St8sia6) localizes in the ER and enhances the anchorage-independent cell growth in cancer. (PMID:35390672)
• ST8SIA6-AS1 contributes to hepatocellular carcinoma progression by targeting miR-142-3p/HMGA1 axis. (PMID:36635290)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	st8sia6	ENSDARG00000021195
mus_musculus	St8sia6	ENSMUSG00000003418
rattus_norvegicus	St8sia6	ENSRNOG00000064205

Paralogs (5): ST8SIA5 (ENSG00000101638), ST8SIA1 (ENSG00000111728), ST8SIA4 (ENSG00000113532), ST8SIA2 (ENSG00000140557), ST8SIA3 (ENSG00000177511)

Protein

Protein identifiers

Alpha-2,8-sialyltransferase 8F — P61647 (reviewed: P61647)

Alternative names: Sialyltransferase 8F, Sialyltransferase St8Sia VI

All UniProt accessions (3): P61647, A0A3B3ITM3, H0Y405

UniProt curated annotations — full annotation on UniProt →

Function. Alpha-2,8-sialyltransferase that prefers O-glycans to N-glycans or glycolipids as acceptor substrates. The minimal acceptor substrate is the NeuAc-alpha-2,3(6)-Gal sequence at the non-reducing end of their carbohydrate groups.

Subcellular location. Golgi apparatus membrane.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 29 family.

RefSeq proteins (2): NP_001004470, NP_001332890 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001675	Glyco_trans_29	Family
IPR012163	Sialyl_trans	Family
IPR038578	GT29-like_sf	Homologous_superfamily
IPR050943	Glycosyltr_29_Sialyltrsf	Family

Pfam: PF00777

Enzyme classification (BRENDA):

• EC 2.4.99.8 — alpha-N-acetylneuraminate alpha-2,8-sialyltransferase (BRENDA: 0 organisms, 0 substrates, 0 inhibitors, 0 Km, 0 kcat entries)

Catalyzed reactions (Rhea), 10 shown:

• a ganglioside GM3 (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a ganglioside GD3 (d18:1(4E)) + CMP + H(+) (RHEA:41760)
• a ganglioside GD1a (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a ganglioside GT1a (d18:1(4E)) + CMP + H(+) (RHEA:41768)
• a ganglioside GT1b (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a ganglioside GQ1b (d18:1(4E)) + CMP + H(+) (RHEA:41772)
• a ganglioside GM1b (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = a ganglioside GD1c (d18:1(4E)) + CMP + H(+) (RHEA:47576)
• a ganglioside GM3 + CMP-N-acetyl-beta-neuraminate = a ganglioside GD3 + CMP + H(+) (RHEA:48288)
• a ganglioside GD1a + CMP-N-acetyl-beta-neuraminate = a ganglioside GT1a + CMP + H(+) (RHEA:48912)
• a ganglioside GM1b + CMP-N-acetyl-beta-neuraminate = a ganglioside GD1c + CMP + H(+) (RHEA:48916)
• a ganglioside GM4 (d18:1(4E)) + CMP-N-acetyl-beta-neuraminate = an N-acetyl-alpha-neuraminosyl-(2->8)-N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1<->1’)-N-acylsphing-4-enine + CMP + H(+) (RHEA:48924)
• N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1<->1’)-ceramide + CMP-N-acetyl-beta-neuraminate = N-acetyl-alpha-neuraminosyl-(2->8)-N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1<->1’)-ceramide + CMP + H(+) (RHEA:48928)
• a ganglioside GT1b + CMP-N-acetyl-beta-neuraminate = a ganglioside GQ1b + CMP + H(+) (RHEA:48932)

UniProt features (14 total): glycosylation site 4, binding site 3, topological domain 2, disulfide bond 2, chain 1, transmembrane region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P61647-F1	86.04	0.72

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 370 (proton donor/acceptor)

Ligand- & substrate-binding residues (3): 214; 236–238; 322–324

Disulfide bonds (2): 186–335, 200–395

Glycosylation sites (4): 151, 196, 66, 93

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-4085001	Sialic acid metabolism
R-HSA-975577	N-Glycan antennae elongation
R-HSA-392499	Metabolism of proteins
R-HSA-446193	Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
R-HSA-446203	Asparagine N-linked glycosylation
R-HSA-446219	Synthesis of substrates in N-glycan biosythesis
R-HSA-597592	Post-translational protein modification
R-HSA-948021	Transport to the Golgi and subsequent modification
R-HSA-975576	N-glycan antennae elongation in the medial/trans-Golgi

MSigDB gene sets: 146 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_UP, GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, GOBP_N_GLYCAN_PROCESSING, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_GLYCOLIPID_BIOSYNTHETIC_PROCESS, GOBP_PROTEIN_N_LINKED_GLYCOSYLATION, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_CERAMIDE_BIOSYNTHETIC_PROCESS, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_SPHINGOLIPID_METABOLIC_PROCESS, GOBP_AMIDE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GOBP_AMIDE_BIOSYNTHETIC_PROCESS, GOBP_GLYCOSPHINGOLIPID_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS

GO Biological Process (10): ganglioside biosynthetic process (GO:0001574), blastocyst hatching (GO:0001835), N-glycan processing (GO:0006491), protein O-linked glycosylation (GO:0006493), glycoprotein metabolic process (GO:0009100), glycolipid biosynthetic process (GO:0009247), oligosaccharide metabolic process (GO:0009311), carbohydrate biosynthetic process (GO:0016051), obsolete protein glycosylation (GO:0006486), lipid metabolic process (GO:0006629)

GO Molecular Function (4): alpha-N-acetylneuraminate alpha-2,8-sialyltransferase activity (GO:0003828), sialyltransferase activity (GO:0008373), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757)

GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Asparagine N-linked glycosylation	2
Synthesis of substrates in N-glycan biosythesis	1
N-glycan antennae elongation in the medial/trans-Golgi	1
Post-translational protein modification	1
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein	1
Metabolism of proteins	1
Transport to the Golgi and subsequent modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycoprotein biosynthetic process	2
carbohydrate metabolic process	2
ganglioside metabolic process	1
glycosphingolipid biosynthetic process	1
ceramide biosynthetic process	1
blastocyst development	1
hatching	1
protein N-linked glycosylation	1
protein metabolic process	1
carbohydrate derivative metabolic process	1
glycolipid metabolic process	1
lipid biosynthetic process	1
carbohydrate derivative biosynthetic process	1
biosynthetic process	1
primary metabolic process	1
sialyltransferase activity	1
glycosyltransferase activity	1
catalytic activity	1
transferase activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

714 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ST8SIA6	AHSG	P02765	764
ST8SIA6	ST6GALNAC6	Q969X2	634
ST8SIA6	SIGLEC7	Q9Y286	614
ST8SIA6	ST3GAL6	Q9Y274	544
ST8SIA6	ST6GALNAC3	Q8NDV1	533
ST8SIA6	ST3GAL5	Q9UNP4	491
ST8SIA6	ST3GAL4	Q11206	441
ST8SIA6	SPTSSB	Q8NFR3	432
ST8SIA6	LCLAT1	Q6UWP7	431
ST8SIA6	TSPAN19	P0C672	423
ST8SIA6	LINC03043	A4D0Y5	419
ST8SIA6	FAM216B	Q8N7L0	402
ST8SIA6	ARSI	Q5FYB1	390
ST8SIA6	RTL5	Q5HYW3	386
ST8SIA6	MGAT4C	Q9UBM8	381

IntAct

2 interactions, top by confidence:

A	B	Type	Score
CRP	QSOX1	psi-mi:“MI:0914”(association)	0.530

BioGRID (3): ST8SIA6 (Synthetic Growth Defect), ST8SIA6 (Affinity Capture-MS), XRCC6 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A6NG13, A7RX69, A8E7N9, E7F9T0, F1QWZ4, F1S5L4, I1FQB6, O15466, O35696, O43173, O97827, P23613, P38566, P48794, P61643, P61644, P61645, P61646, P61647, P61648, P70126, P85857, P97564, Q07977, Q17678, Q1LYL8, Q26974, Q4V8F8, Q5GJ77, Q5RCN4, Q61089, Q61586, Q64689, Q64690, Q64692, Q66KL4, Q6ZXC8, Q6ZXC9, Q765H6, Q80TS3

Diamond homologs: O15466, O35696, O43173, P61642, P61643, P61644, P61645, P61646, P61647, P61648, P70126, Q07977, Q11200, Q64687, Q64689, Q64690, Q64692, Q6DNG6, Q6H8M7, Q6ZXA0, Q6ZXC8, Q6ZXC9, Q6ZXD2, Q8K4T1, Q92185, Q92186, Q92187, A2WX64, A2XVC2, A2ZI41, P13721, P61132, Q11203, Q11204, Q16842, Q2QXM3, Q2R2B1, Q64685, Q6KB58, Q6ZH45

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2259 predictions. Top by Δscore:

Variant	Effect	Δscore
10:17321344:TAT:T	acceptor_gain	1.0000
10:17321345:ATC:A	acceptor_loss	1.0000
10:17321346:TC:T	acceptor_loss	1.0000
10:17321347:C:CC	acceptor_gain	1.0000
10:17323060:CTT:C	donor_loss	1.0000
10:17323061:TTA:T	donor_loss	1.0000
10:17323062:TA:T	donor_loss	1.0000
10:17323063:A:AC	donor_gain	1.0000
10:17323063:AC:A	donor_loss	1.0000
10:17323064:C:CC	donor_gain	1.0000
10:17323064:CTT:C	donor_gain	1.0000
10:17323064:CTTCA:C	donor_gain	1.0000
10:17325994:T:TA	donor_gain	1.0000
10:17331407:CCA:C	donor_gain	1.0000
10:17390627:CA:C	acceptor_gain	1.0000
10:17390628:A:C	acceptor_gain	1.0000
10:17394259:TGGGG:T	donor_gain	1.0000
10:17321342:CATAT:C	acceptor_gain	0.9900
10:17321343:ATAT:A	acceptor_gain	0.9900
10:17321351:C:CT	acceptor_gain	0.9900
10:17323057:CTACT:C	donor_loss	0.9900
10:17323058:TACTT:T	donor_loss	0.9900
10:17323059:ACTTA:A	donor_loss	0.9900
10:17323063:ACTT:A	donor_gain	0.9900
10:17323064:CT:C	donor_gain	0.9900
10:17323064:CTTC:C	donor_gain	0.9900
10:17323153:TACAC:T	acceptor_gain	0.9900
10:17323155:CAC:C	acceptor_gain	0.9900
10:17323156:ACC:A	acceptor_loss	0.9900
10:17323158:CTGA:C	acceptor_loss	0.9900

AlphaMissense

2617 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:17321088:A:C	S329R	0.997
10:17321088:A:T	S329R	0.997
10:17321090:T:G	S329R	0.997
10:17321083:G:T	A331E	0.994
10:17323151:G:C	N214K	0.994
10:17323151:G:T	N214K	0.994
10:17327092:C:G	C186S	0.993
10:17327093:A:T	C186S	0.993
10:17320967:G:C	H370D	0.992
10:17321046:G:C	F343L	0.992
10:17321046:G:T	F343L	0.992
10:17321048:A:G	F343L	0.992
10:17321071:C:G	C335S	0.992
10:17321071:C:T	C335Y	0.992
10:17321072:A:T	C335S	0.992
10:17321070:A:C	C335W	0.991
10:17321072:A:G	C335R	0.991
10:17321144:A:G	W311R	0.991
10:17321144:A:T	W311R	0.991
10:17327083:A:T	V189D	0.991
10:17327093:A:G	C186R	0.991
10:17321084:C:G	A331P	0.990
10:17321110:G:A	S322F	0.990
10:17321117:G:T	R320S	0.990
10:17321142:C:A	W311C	0.990
10:17321142:C:G	W311C	0.990
10:17327014:C:A	R212M	0.990
10:17327020:A:T	V210D	0.990
10:17321116:C:G	R320P	0.989
10:17323157:C:A	R212S	0.989

dbSNP variants (sampled 300 via entrez): RS1000023944 (10:17434666 C>G,T), RS1000035308 (10:17341590 A>G), RS1000038980 (10:17358819 C>A,T), RS1000069208 (10:17357365 T>G), RS1000071576 (10:17352488 A>T), RS1000075909 (10:17420343 C>G,T), RS1000091975 (10:17389854 G>A,C), RS1000092471 (10:17428626 C>T), RS1000106161 (10:17437952 A>G), RS1000174232 (10:17375771 A>C), RS1000232364 (10:17454785 T>A), RS1000260037 (10:17363741 A>T), RS1000273964 (10:17451788 A>C,G), RS1000286864 (10:17446050 C>T), RS1000317323 (10:17330618 A>C)

Disease associations

OMIM: gene MIM:610139 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST000323_12	Response to treatment for acute lymphoblastic leukemia	9.000000e-08
GCST004691_19	Huntington’s disease progression	9.000000e-06
GCST005166_10	GIP levels in response to oral glucose tolerance test (120 minutes)	9.000000e-06
GCST006585_2487	Blood protein levels	3.000000e-07
GCST008790_36	Urinary albumin-to-creatinine ratio	3.000000e-11
GCST008791_23	Microalbuminuria	1.000000e-09

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0008336	disease progression measurement
EFO:0004307	glucose tolerance test
EFO:0008464	glucose-dependent insulinotropic peptide measurement
EFO:0007778	urinary albumin to creatinine ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Aflatoxin B1	decreases methylation, increases methylation	2
GSK-J4	increases expression	1
triphenyl phosphate	affects expression	1
nickel sulfate	increases expression	1
theaflavin-3,3’-digallate	affects expression	1
Benzo(a)pyrene	affects methylation	1
Coumestrol	affects cotreatment, increases expression, affects reaction	1
Oxygen	increases expression	1
Valproic Acid	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer